ADAR1 Capital Fuels InMed Surge Ahead of Mentari Merger, Investors Eye Potential Breakout ?

ADAR1 Capital’s Latest Surge in InMed Shares

ADAR1 Capital Management, LLC made a sizable injection of capital into InMed Pharmaceuticals on May 19, 2026, purchasing 68,551 shares at an average price of $1.60, 200,000 shares at $1.56, and another 200,000 shares at $1.50—totaling 468,551 new shares. With each transaction reported as a “buy,” the fund’s post‑transaction holdings climbed to 800,000 shares, up from 331,449 shares reported earlier in the year. The transactions were executed at a price only marginally below the closing price of $1.61, reflecting a modest 0.08 % discount to market, while the broader market was still riding a 166.6 % weekly rally. The spike in social‑media buzz (190 %) and a sentiment score of +52 suggest that these purchases were viewed favorably by the community, likely buoyed by the positive narrative around InMed’s merger with Mentari Therapeutics.

What the Buy Signals for Investors

From an investor‑perspective, ADAR1’s continued buying activity signals confidence in the merger’s strategic value. InMed’s deal with Mentari promises to broaden its therapeutic portfolio into migraine prevention—a high‑growth segment—and to unlock additional capital through a planned private placement. By purchasing shares at a slight discount, ADAR1 is positioning itself to benefit from any upside once the combined company realizes synergies and completes the funding round. For shareholders, the infusion of capital could accelerate product development and bring the company closer to regulatory milestones, potentially driving a longer‑term price appreciation that offsets the current negative price‑earnings ratio of –0.67.

ADAR1 Capital’s Historical Profile

ADAR1 Capital Management, LLC has a history of opportunistic, short‑term buy‑and‑hold strategies in the biotech space. Their most recent filing shows a “holding” status with 331,449 shares as of May 21, 2026, indicating that the fund typically consolidates positions after an acquisition. The fund’s purchase prices in the current filing—ranging from $1.50 to $1.60—reflect a pattern of buying on dips or during periods of heightened market volatility. While the fund’s transactions are largely passive, its consistent stake in InMed aligns with its broader focus on cannabis‑based therapeutics and emerging biopharma platforms, suggesting a belief that InMed’s proprietary cannabinoid platform will generate substantial value over the next few years.

Industry Context and the Merger’s Implications

InMed’s merger with Mentari Therapeutics represents a strategic pivot toward migraine therapy, leveraging Mentari’s pipeline and commercial expertise. The combined entity is set to list on the Nasdaq Capital Market under the Mentari name, potentially offering better liquidity and visibility. The planned private placement will likely raise significant capital, giving the company the runway to advance clinical trials and navigate regulatory hurdles—critical steps for a biotech firm with a negative earnings record and a low 52‑week low of $0.575. If the merger proceeds smoothly, ADAR1’s position could be a catalyst for a breakout, especially if the market perceives the combined company’s valuation as undervalued relative to the broader healthcare sector.

Bottom Line for Market Watchers

ADAR1’s recent buying spree is a positive barometer for InMed’s prospects, particularly in light of the Mentari merger and upcoming private placement. The fund’s track record of opportunistic acquisitions in the biotech niche, coupled with the surge in social media sentiment, suggests a bullish outlook for investors who believe in the long‑term potential of cannabis‑based therapies. As the company navigates regulatory approvals and capital raises, watch for any further insider activity that could confirm the market’s confidence—or signal a shift in strategy.